The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models

International Journal of Cancer

Volumn 131, Issue 1, 2012, Pages 8-17

  Hatiboglu, Mustafa Aziz ^a   Kong, Ling Yuan ^a   Wei, Jun ^a   Wang, Yongtao ^a   McEnery, Kayla Anne ^a   Fuller, Gregory N ^a   Qiao, Wei ^a   Davies, Michael A ^a   Priebe, Waldemar ^a   Heimberger, Amy B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

cyclophosphamide; melanoma; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; STAT3 PROTEIN; UNCLASSIFIED DRUG; WP 1066;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL POPULATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; IC 50; IMMUNOCOMPETENT CELL; MELANOMA; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PYRIDINES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT; TYRPHOSTINS;

EID: 84860218875     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26307     Document Type: Article

References (49)

1. Sampson JH, Carter JH, Jr, Friedman AH, Seigler HF,. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88: 11-20.
2. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, Tatagiba M, Brossart P, Garbe C,. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102: 1213-8.
3. Borne E, Desmedt E, Duhamel A, Mirabel X, Dziwniel V, Maire C, Florin V, Martinot V, Penel N, Vercambre-Darras S, Mortier L,. Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs 2010;28:684-9.
4. Gunturu KS, Meehan KR, Mackenzie TA, Crocenzi TS, McDermott D, Usherwood EJ, Margolin KA, Crosby NA, Atkins MB, Turk MJ, Ahonen C, Fuse S, Clark JI, Fisher JL, Noelle RJ, Ernstoff MS,. Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol 2010; 28: 1196-202.
5. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bernard Bonnotte B, Martin F,. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34: 336-44.
6. Mihalyo MA, Doody AD, McAleer JP, Nowak EC, Long M, Yang Y, Adler AJ,. In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy. J Immunol 2004; 172: 5338-45.
7. North RJ,. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 155: 1063-74.
8. Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F,. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 1998; 101: 429-41.
9. Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, Wang Y, Cheng X, Li YQ, Xia JC, Masucci M, Zeng YX,. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 2007; 56: 1597-604.
10. Taieb J, Chaput N, Schartz N, Roux S, Novault S, Menard C, Ghiringhelli F, Terme M, Carpentier AF, Darrasse-Jese G, Lemonnier F, Zitvogel L,. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 2006; 176: 2722-9.
11. Berd D, Mastrangelo MJ,. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 1987; 47: 3317-21.
12. Polak L, Turk JL,. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 1974; 249: 654-6.
13. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E,. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95: 2024-30.
14. Matar P, Rozados VR, Gonzalez AD, Dlugovitzky DG, Bonfil RD, Scharovsky OG,. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur J Cancer 2000; 36: 1060-6.
15. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS,. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002; 62: 2731-5.
16. Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS,. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005; 65: 7045-51.
17. Cruz-Munoz W, Man S, Kerbel RS,. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin Cancer Res 2009; 15: 4867-74.
18. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V,. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003; 63: 8408-13.
19. Shiraga E, Barichello JM, Ishida T, Kiwada H,. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. Int J Pharm 2008; 353: 65-73.
20. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Jr, Sampson JH, et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 2008; 14: 5759-68.
21. Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB,. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 2009; 58: 1023-32.
22. Kortylewski M, Yu H,. Stat3 as a potential target for cancer immunotherapy. J Immunother 2007; 30: 131-9.
23. Yu H, Kortylewski M, Pardoll D,. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
24. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10: 48-54.
25. Kortylewski M, Jove R, Yu H,. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005; 24: 315-27.
26. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S,. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004; 23: 3550-60.
27. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R, Huang S,. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2006; 66: 3188-96.
28. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, Frank DA, Ritz J,. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571-9.
29. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH,. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003; 9: 4247-54.
30. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD,. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA 1996; 93: 10399-404.
31. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H,. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009; 206: 1457-64.
32. Kong LY, Wu A, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, Heimberger AB,. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immune therapeutic response. Clin Cancer Res 2010; 10: 06.
33. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE, II, Bigner DD, Dranoff G, Sampson JH,. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66: 3294-302.
34. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
35. Mantel N,. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
36. Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB,. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res 2010;16: 2550-61.
37. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A,. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009; 27: 1075-81.
38. Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C,. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005; 103: 2584-9.
39. Cruz-Munoz W, Man S, Xu P, Kerbel RS,. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res 2008; 68: 4500-5.
40. Genka S, Deutsch J, Stahle PL, Shetty UH, John V, Robinson C, Rapoport SI, Greig NH,. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother Pharmacol 1990; 27: 1-7.
41. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J,. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-86.
42. Iwamoto Y, Fujita Y, Sugioka Y,. YIGSR, a synthetic laminin peptide, inhibits the enhancement by cyclophosphamide of experimental lung metastasis of human fibrosarcoma cells. Clin Exp Metastasis 1992; 10: 183-9.
43. Yang M, Jiang P, An Z, Baranov E, Li L, Hasegawa S, Al-Tuwaijri M, Chishima T, Shimada H, Moossa AR, Hoffman RM,. Genetically fluorescent melanoma bone and organ metastasis models. Clin Cancer Res 1999; 5: 3549-59.
44. Shahani N, Gourie-Devi M, Nalini A, Raju TR,. Cyclophosphamide attenuates the degenerative changes induced by CSF from patients with amyotrophic lateral sclerosis in the neonatal rat spinal cord. J Neurol Sci 2001; 185: 109-18.
45. Aloisi F, Care A, Borsellino G, Gallo P, Rosa S, Bassani A, Cabibbo A, Testa U, Levi G, Peschle C,. Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. J Immunol 1992; 149: 2358-66.
46. Arndt CA, Balis FM, McCully CL, Colvin OM, Poplack DG,. Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys. Cancer Res 1988; 48: 2113-5.
47. Mahoney DH, Jr., Strother D, Camitta B, Bowen T, Ghim T, Pick T, Wall D, Yu L, Shuster JJ, Friedman H,. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. J Clin Oncol 1996; 14: 382-8.
48. Rosner D, Nemoto T, Lane WW,. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58: 832-9.
49. Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA,. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro Oncol 2002; 4: 268-77.